ABSI
Absci Corporation
NASDAQ · Healthcare · Biotechnology · US
$8.84
+0.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6M | 2.8M | 4.5M | 5.7M | 5.7M |
| Cost of Revenue | 5.6M | 11.7M | 62.5M | 47.6M | 58.9M |
| Gross Profit | (4.0M) | (8.9M) | (57.9M) | (41.8M) | (53.2M) |
| Operating Expenses | |||||
| R&D Expense | 86.5M | 81.4M | 63.9M | 48.1M | 58.9M |
| SG&A Expense | 26.8M | 35.1M | — | — | — |
| General & Admin Expense | 9.2M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 14.0M | (700.0K) | (12.9M) | 25.6M | (5.3M) |
| Total Operating Expenses | 127.3M | 115.8M | 51.0M | 73.7M | 53.6M |
| Cost and Expenses | 132.9M | 127.5M | 113.4M | 121.2M | 112.5M |
| Operating Income (EBIT) | (131.3M) | (124.7M) | (108.9M) | (115.5M) | (106.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 58.0K | 209.0K | 565.0K | 1.0M | 972.0K |
| Net Interest Income | (58.0K) | (209.0K) | (565.0K) | (1.0M) | (972.0K) |
| Other Non-Op Income/Expense | 10.2M | 9.6M | 5.9M | 5.0M | 1.4M |
| Non-Operating Income (excl Interest) | (10.3M) | (9.8M) | (1.4M) | (21.8M) | (2.4M) |
| EBT (Pre-Tax Income) | (121.1M) | (115.1M) | (103.0M) | (110.5M) | (105.4M) |
| Income Tax Expense | — | 69.0K | 70.0K | 100.0K | (461.0K) |
| Bottom Line | |||||
| Net Income | (121.1M) | (115.2M) | (103.1M) | (110.6M) | (104.9M) |
| Earnings from Cont. Ops | (121.1M) | (115.2M) | (103.1M) | (110.6M) | (104.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (121.1M) | (115.2M) | (103.1M) | (110.6M) | (104.9M) |
| Per Share | |||||
| Basic EPS | ($0.80) | ($0.84) | ($0.94) | ($1.20) | ($1.15) |
| Diluted EPS | ($0.80) | ($0.84) | ($0.94) | ($1.20) | ($1.15) |
| Revenue Per Share | $0.01 | $0.02 | $0.04 | $0.06 | $0.06 |
| Shares | |||||
| Basic Shares Outstanding | 157.5M | 136.8M | 110.2M | 92.0M | 90.8M |
| Diluted Shares Outstanding | 157.5M | 136.8M | 110.2M | 92.0M | 90.8M |
| Profitability Metrics | |||||
| EBITDA | (109.9M) | (103.2M) | (94.1M) | (79.7M) | (91.4M) |
| D&A | 11.1M | 11.7M | 13.4M | 14.0M | 13.0M |
| EBIT | (121.0M) | (114.9M) | (107.5M) | (93.7M) | (104.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026